Evidence map›Paper›PMID 24317392›Full record

ArticleThe Journal of investigative dermatology2014

A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.

Maryline Allegra, Damien Giacchero, Coralie Segalen, Nicolas Dumaz, Catherine Butori, Véronique Hofman, Paul Hofman, Jean-Philippe Lacour, Corine Bertolotto, Philippe Bahadoran and 1 more

Abstract readCase ReportsLetter
PubMed Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Aspects of Modern Biobank Activity - Comprehensive Review.Pathology oncology research : POR · 2018
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maryline AllegraEquipe Labellisée par la Ligue Contre le Cancer, Biology and Pathologies of Melanocytes, Equipe 1, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Nice, France; Department of Dermatology, CHU Nice, Nice, France.
Damien GiaccheroDepartment of Dermatology, CHU Nice, Nice, France.
Coralie SegalenEquipe Labellisée par la Ligue Contre le Cancer, Biology and Pathologies of Melanocytes, Equipe 1, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Nice, France.
Nicolas DumazINSERM U976, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
Catherine ButoriIRCAN Equipe 3, and Hospital-Integrated Tumor Biobank, INSERM U 1081, Nice, France.
Véronique HofmanUFR Médecine, Université de Nice-Sophia Antipolis, Nice, France; IRCAN Equipe 3, and Hospital-Integrated Tumor Biobank, INSERM U 1081, Nice, France.
Paul HofmanUFR Médecine, Université de Nice-Sophia Antipolis, Nice, France; IRCAN Equipe 3, and Hospital-Integrated Tumor Biobank, INSERM U 1081, Nice, France.
Jean-Philippe LacourDepartment of Dermatology, CHU Nice, Nice, France; UFR Médecine, Université de Nice-Sophia Antipolis, Nice, France.
Corine BertolottoEquipe Labellisée par la Ligue Contre le Cancer, Biology and Pathologies of Melanocytes, Equipe 1, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Nice, France; UFR Médecine, Université de Nice-Sophia Antipolis, Nice, France.
Philippe BahadoranEquipe Labellisée par la Ligue Contre le Cancer, Biology and Pathologies of Melanocytes, Equipe 1, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Nice, France; Department of Dermatology, CHU Nice, Nice, France; UFR Médecine, Université de Nice-Sophia Antipolis, Nice, France; Clinical Research Centre, CHU Nice, Nice, France. Electronic address: bahadoran.p@chu-nice.fr.
Robert BallottiEquipe Labellisée par la Ligue Contre le Cancer, Biology and Pathologies of Melanocytes, Equipe 1, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Nice, France; Department of Dermatology, CHU Nice, Nice, France; UFR Médecine, Université de Nice-Sophia Antipolis, Nice, France. Electronic address: ballotti@unice.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAntineoplastic AgentsBenzamidesCell Line, TumorHumansImatinib MesylateMelanomaPiperazinesPoint MutationProto-Oncogene Proteins c-kitPyrimidinesSignal TransductionSkin NeoplasmsAntineoplastic AgentsBenzamidesImatinib MesylatePiperazinesProto-Oncogene Proteins c-kitPyrimidines

Identifiers

PMID24317392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.